2021
Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program
Akwo EA, Robinson-Cohen C, Chung CP, Shah SC, Brown NJ, Ikizler TA, Wilson OD, Rowan BX, Shuey MM, Siew ED, Luther JM, Giri A, Hellwege JN, Edwards D, Roumie CL, Tao R, Tsao PS, Gaziano JM, Wilson PWF, O’Donnell C, Edwards TL, Kovesdy CP, Hung AM, Program O. Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program. Hypertension 2021, 78: 376-386. PMID: 34148359, PMCID: PMC8364328, DOI: 10.1161/hypertensionaha.120.16181.Peer-Reviewed Original Research
2017
Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery
Shuey MM, Billings FT, Wei S, Milne GL, Nian H, Yu C, Brown NJ. Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery. PLOS ONE 2017, 12: e0175292. PMID: 28552948, PMCID: PMC5446112, DOI: 10.1371/journal.pone.0175292.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseCardiac surgery cohortSoluble epoxide hydrolaseCardiac surgeryKidney injurySurgery cohortAcute Kidney Injury Network criteriaIncidence of AKIPostoperative acute kidney injuryPercent of patientsGlomerular filtration rateBody mass indexAssociation of gainsRenal injuryCardiopulmonary bypassWhite patientsMass indexKidney diseaseFiltration ratePharmacological strategiesDiscovery cohortNetwork criteriaVariant carriersSEH activity
2015
Oxidative Stress Biomarkers and Incidence of Postoperative Atrial Fibrillation in the Omega‐3 Fatty Acids for Prevention of Postoperative Atrial Fibrillation (OPERA) Trial
Wu JH, Marchioli R, Silletta MG, Masson S, Sellke FW, Libby P, Milne GL, Brown NJ, Lombardi F, Damiano RJ, Marsala J, Rinaldi M, Domenech A, Simon C, Tavazzi L, Mozaffarian D. Oxidative Stress Biomarkers and Incidence of Postoperative Atrial Fibrillation in the Omega‐3 Fatty Acids for Prevention of Postoperative Atrial Fibrillation (OPERA) Trial. Journal Of The American Heart Association 2015, 4: e001886. PMID: 25994442, PMCID: PMC4599415, DOI: 10.1161/jaha.115.001886.Peer-Reviewed Original ResearchConceptsEnd of surgeryOxidative stress biomarkersPostoperative atrial fibrillationPostoperative day 2Stress biomarkersAtrial fibrillationOxidative stressDay 2Omega-3 fatty acidsCardiac surgery patientsAtrial Fibrillation (ARISTOTLE) trialKey pathogenic rolePostoperative day 10Urine F2-isoprostanesAssociation of biomarkersBaseline biomarker levelsElevated oxidative stressAnimal study resultsPerioperative courseHospital dischargeSurgery patientsMedication useSurgery typeUrine levelsBiomarker levels
2013
Plasma Phospholipid Omega‐3 Fatty Acids and Incidence of Postoperative Atrial Fibrillation in the OPERA Trial
Wu JH, Marchioli R, Silletta MG, Macchia A, Song X, Siscovick DS, Harris WS, Masson S, Latini R, Albert C, Brown NJ, Lamarra M, Favaloro RR, Mozaffarian D. Plasma Phospholipid Omega‐3 Fatty Acids and Incidence of Postoperative Atrial Fibrillation in the OPERA Trial. Journal Of The American Heart Association 2013, 2: e000397. PMID: 24145742, PMCID: PMC3835252, DOI: 10.1161/jaha.113.000397.Peer-Reviewed Original ResearchConceptsFish oil supplementationMorning of surgeryPostoperative atrial fibrillationCardiac surgeryOil supplementationDocosapentaenoic acidAtrial fibrillationDocosahexaenoic acidEicosapentaenoic acidShort-term fish oil supplementationPUFA levelsOmega-3 fatty acidsCardiac surgery patientsPlasma phospholipid nPostoperative day 10Substantial interindividual variabilityOPERA trialPoAF episodesPlacebo supplementationPrimary endpointSecondary endpointsHospital dischargeSurgery patientsAntiarrhythmic potentialFatty acids
2012
Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies
Brown NJ. Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. International Journal Of Cardiology Cardiovascular Risk And Prevention 2012, 6: 163-168. PMID: 22433315, PMCID: PMC3422131, DOI: 10.1016/j.jash.2012.02.003.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1Cardiovascular eventsDipeptidyl peptidase IV inhibitorsAntidiabetic agentsPeptidase IV inhibitorsBlood pressureClinical trialsPeptide-1Animal modelsType 2 diabetes mellitusIncretin-based agentsBlood pressure effectsIncretin-based therapiesIV inhibitorsLarge clinical trialsFavorable effectIschemia/reperfusionTight glucose controlOverweight diabeticsCardiovascular effectsCardiovascular riskDiabetes mellitusIntensive therapyGlucose controlThiazolidinedione rosiglitazone